Inflammasome-Targeted Therapeutics Market
完整報告名稱與涵蓋範圍
Inflammasome-Targeted Therapeutics Market Size, Share & Trends Analysis Report, By Target (NLRP3 Inhibitors, IL-1 Pathway Biologics, Other Inflammasome Components (NLRP1, AIM2, Caspase-1, Gasdermin D)), By Indication (Cardiovascular and Metabolic Inflammation, Neuroinflammation and Neurodegeneration, Autoinflammatory and Rare Diseases, Dermatology, Gout and Musculoskeletal Inflammation), By Development Stage (Preclinical and Phase 1, Phase 2 and Phase 3, Approved and Commercial), By End User, By Region, and Segment Forecasts, 2026-2035
報告摘要
The inflammasome-targeted therapeutics market covers medicines that inhibit inflammasome activation or its downstream signalling, including approved IL-1 pathway biologics used for autoinflammatory diseases and a clinical pipeline of oral NLRP3 inhibitors and agents directed at other inflammasome components. Broad anti-inflammatory drugs such as corticosteroids and TNF inhibitors are excluded. Because oral NLRP3 inhibitors have not yet been approved, forecast revenue beyond the IL-1 biologic baseline is modelled from expected approval timing and indication scope.
The rationale rests on genetic and clinical evidence that NLRP3-driven interleukin-1 signalling contributes to cardiovascular events, obesity-related inflammation, gout, neurodegeneration and a group of rare autoinflammatory syndromes. Large pharmaceutical companies acquired early NLRP3 platforms and have advanced brain-penetrant and peripherally restricted molecules into mid-stage trials, while smaller companies pursue gasdermin D and caspase-1 approaches. Trial design in chronic inflammatory conditions, biomarker selection and the safety expectations for long-term innate immune suppression will determine which indications open first, with cardiometabolic and dermatologic programs among the most advanced.
Development is concentrated in the United States, Europe and increasingly China, where several NLRP3 candidates originated. The competitive picture combines the IL-1 biologic franchise holders, pharmaceutical groups with acquired NLRP3 assets and specialist inflammasome biotechnology companies.
The InsightAce study delivers revenue forecasts in US$ across all target, indication, development stage and end user and regional segments for 2026-2035, alongside segment-level trend analysis, competitive landscape assessment and detailed company profiling.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Inflammasome-Targeted Therapeutics Market Snapshot
Chapter 4. Global Inflammasome-Targeted Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Target Estimates & Trend Analysis
5.1. Target & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Target:
5.2.1. NLRP3 Inhibitors
5.2.2. IL-1 Pathway Biologics
5.2.3. Other Inflammasome Components (NLRP1, AIM2, Caspase-1, Gasdermin D)
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Cardiovascular and Metabolic Inflammation
6.2.2. Neuroinflammation and Neurodegeneration
6.2.3. Autoinflammatory and Rare Diseases
6.2.4. Dermatology, Gout and Musculoskeletal Inflammation
Chapter 7. Market Segmentation 3: By Development Stage Estimates & Trend Analysis
7.1. Development Stage & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Development Stage:
7.2.1. Preclinical and Phase 1
7.2.2. Phase 2 and Phase 3
7.2.3. Approved and Commercial
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. End User & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
8.2.1. Hospitals and Specialty Clinics
8.2.2. Retail and Specialty Pharmacies
Chapter 9. Inflammasome-Targeted Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Novartis AG
11.2. Roche Holding AG (Inflazome)
11.3. Ventus Therapeutics Inc.
11.4. NodThera Ltd.
11.5. Zydus Lifesciences Ltd.
11.6. Olatec Therapeutics LLC
11.7. Sobi (Swedish Orphan Biovitrum AB)
11.8. Novo Nordisk A/S
11.9. BioAge Labs, Inc.
11.10. Halia Therapeutics, Inc.
11.11. Zomagen Biosciences Ltd.
11.12. Regeneron Pharmaceuticals, Inc.
11.13. Eli Lilly and Company
11.14. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
11.15. Bristol Myers Squibb
圖表清單 List of Tables & Figures
Table 1. Global Inflammasome-Targeted Therapeutics Market Revenue Forecast by Target, 2026-2035 (US$ Mn)
Figure 1. Global Inflammasome-Targeted Therapeutics Market Segmentation Overview
Table 2. Global Inflammasome-Targeted Therapeutics Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Inflammasome-Targeted Therapeutics Market Share by Target, 2026 & 2035
Table 3. Global Inflammasome-Targeted Therapeutics Market Revenue Forecast by Development Stage, 2026-2035 (US$ Mn)
Figure 3. Inflammasome-Targeted Pipeline by Target, Indication and Phase, 2026
Table 4. Global Inflammasome-Targeted Therapeutics Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 4. Global Inflammasome-Targeted Therapeutics Market Share by Indication, 2026 & 2035
Table 5. North America Inflammasome-Targeted Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Peripheral Versus Brain-Penetrant NLRP3 Inhibitor Positioning by Indication
Table 6. Europe Inflammasome-Targeted Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Asia Pacific Inflammasome-Targeted Therapeutics Growth Opportunity Analysis
Table 7. Asia Pacific Inflammasome-Targeted Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Expected Approval Timeline and Revenue Inflection for Oral NLRP3 Inhibitors
Table 8. Latin America Inflammasome-Targeted Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Competitive Positioning of Key Inflammasome-Targeted Therapeutics Market Participants
Table 9. Middle East & Africa Inflammasome-Targeted Therapeutics Market Revenue by Country, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們